![Kaplan--Meier survival curves: time in days from estimated date of seroconversion to CD4\<350 cells/mm^3^, according to race (white vs. non-white).](JIAS-19-21020-g001){#F0001_21020}

###### 

Baseline characteristics of study population

                                          Total (*n*=127)       Naïve patients (*n*=100)   Treated patients (*n*=27)
  ----------------------- --------------- --------------------- -------------------------- ---------------------------
  Sex                     Male            103 (81.1)            87 (87.0)                  16 (59.3)
  Age at diagnosis        Median (IQR)    40 (30 to 50)         47 (31 to 50)              34 (25 to 43)
  Year of diagnosis       Median (IQR)    2012 (2009 to 2015)   2014 (2012 to 2015)        2005 (2000 to 2011)
  Country of origin       Aruba           74 (58.3)             59 (59.0)                  15 (55.6)
                          Colombia        18 (14.2)             15 (15.0)                  3 (11.1)
                          Venezuela       10 (7.9)              5 (5.0)                    5 (18.5)
                          Netherlands     5 (3.9)               5 (5.0)                    0
                          Other           20 (15.7)             16 (16.0)                  4 (14.8)
  Route of transmission   MSM             69 (54.3)             59 (59.0)                  10 (37)
                          Heterosexual    46 (36.2)             23 (23.0)                  13 (48.1)
  Country of infection    Aruba           104 (81.9)            85 (85.0)                  19 (70.4)
                          Outside Aruba   11 (8.7)              7 (7.0)                    4 (14.8)
                          Unknown         9 (7.1)               6 (6.0)                    3 (11.1)
  Log HIV RNA load        Median (IQR)    5.0 (4.0--6.0)        5.0 (4.0--6.0)             4.08 (2.58--5.58)
  CD4 count               Median (IQR)    310 (91--529)         305 (80--530)              315 (100--530)
  AIDS at diagnosis                       26 (20.5)             23 (23.0)                  3 (11.5)
  Subtype B                               120 (94.5)            95 (95.0)                  25 (92.6)

###### 

Renal safety endpoints

  Median (Q1,Q3) per cent change from baseline (unless otherwise noted)   E/C/F/TAF            E/C/F/TDF             Significance
  ----------------------------------------------------------------------- -------------------- --------------------- --------------
  eGFR Cockcroft--Gault (mL/min) (change from baseline)                   −2.0 (−12.4, 9.4)    −7.5 (−17.4, 2.9)     *p*\<.0001
  Urine protein/Cr                                                        −9.1 (−39.6, 36.0)   16.2 (−22.5, 81.5)    *p*\<.0001
  Urine albumin/Cr                                                        −5.2 (−35.7, 30.1)   4.9 (−32.7, 60.0)     *p*\<.0001
  β-2 Microglobulin/Cr                                                    −32.1 (−61.0, 4.2)   33.5 (−27.8, 230.7)   *p*\<.0001
  Retinol-binding protein/Cr                                              13.8 (−18.8, 66.1)   74.2 (10.4, 192.3)    *p*\<.0001

![Changes in quantitative proteinuria in subjects ≥50 years.](JIAS-19-21032-g001){#F0001_21032}

![Changes in tubular proteinuria in subjects ≥50 years.](JIAS-19-21032-g002){#F0002_21032}

###### 

Baseline characteristics (N=752)

  Characteristics (N=752)                                   Median           IQR
  --------------------------------------------------------- ---------------- ----------------
  **Age (years)**                                           34               27 to 42
  **Education (years)**                                     11.1             8 to 15
  **CD4 count (cells/mL)**                                  443              218 to 614
  **Viral load (copies/mL)**                                32509            2590 to 138000
                                                            **Mean**         **SD**
                                                                             
  **Weight (kg)**                                           67.4             14.84
  **Height (cm)**                                           168.72           21
  **Blood pressure (mm Hg)**                                                 
  -Systolic blood pressure                                  111.31           13.51
  -Diastolic blood pressure                                 70.46            9.9
                                                            **Percentage**   **95% CI**
                                                                             
  **Male at birth**                                         86               84 to 89
  **White race**                                            41               37 to 44
  **Health coverage**                                                        
  -Public                                                   88.1             85.8 to 90.4
  -Private                                                  6.8              5.0 to 8.6
  -Social security                                          5.1              3.5 to 6.7
  **Mode of transmission**                                                   
  -MSM/bisexual                                             60.6             57.11 to 11.09
  -Heterosexual                                             33.8             30.42 to 37.18
  -Missing data                                             3.9              2.5 to 5.28
  -Parenteral                                               0.7              0.1 to 1.3
  -Unknown                                                  0.9              0.23 to 1.57
  -Vertical                                                 0.1              0 to 0.33
  **Symptoms at diagnosis (N=276)**                                          
  -Weight loss                                              14.6             10.43 to 18.77
  -Fever \>2 weeks                                          8.4              5.13 to 11.67
  -Chronic diarrhoea                                        6.5              3.59 to 9.41
  -Lymphadenopathies                                        2.9              0.92 to 4.88
  -Herpes                                                   2.7              0.79 to 4.16
  -Oral candidiasis                                         1.5              0.07 to 2.93
  -Oral leucoplakia                                         0.1              0 to 0.47
  **Patients showing progression of disease at baseline**   23.8             20.76 to 26.84
  **Other conditions**                                      18.1             15.35 to 20.85
  **Current habits (self-reported)**                                         
  Smoking                                                   45               39.13 to 50.87
  Drugs                                                     8.6              5.29 to 11.91
  Alcohol consumption                                       28.3             22.99 to 33.61

Age was significantly lower in Mexican population (34.71 vs. 38.27, mean difference 3.5795%CI: −5.46 to 1.66) as well as systolic blood pressure and diastolic blood pressure (108.32 vs. 120.58, *p*=0.04 and 68.87 vs. 75.43, *p*=0.01). The most frequent non-HIV-related conditions found were sexually transmitted disease (N=44) and hypertension (N=33). Co-infection with HCV was found in 11 patients (1.1%; 0.07 to 2.93). HBV was found in 14 patients (1.9%; 0.29 to 3.51).

###### 

SVR12 by treatment history, cirrhosis status, race and GT1 subtype

  Study                             ION 1           ION 2          ION 3          ION 1--3 (combined)   ION 4 (HIV)
  --------------------------------- --------------- -------------- -------------- --------------------- --------------
  Treatment-naïve SVR12 (%)         210/213 (99)                   208/216 (96)   418/429 (97)          138/146 (95)
  Treatment-experienced SVR12 (%)                   102/109 (94)                  102/109 (94)          175/181 (97)
  Cirrhosis SVR12 (%)               32/34 (94)      19/22 (86)                    51/56 (92)            63/67 (94)
  Non-cirrhotic SVR12 (%)           179/179 (100)   83/87 (95)     208/216 (96)   470/482 (98)          250/260 (96)
  Blacks SVR12 (%)                  24/24 (100)     24/24 (100)    40/42 (95)     89/90 (99)            103/115 (90)
  Non-blacks SVR12 (%)              188/190 (99)    78/85 (92)     165/173 (95)   431/448 (96)          215/217 (99)
  GT 1a                             142/145 (98)    82/86 (95)     165/172 (96)   389/403 (97)          239/250 (96)
  GT 1b                             67/67 (100)     20/23 (87)     43/44 (98)     130/134 (97)          74/77 (96)

###### 

Efficacy and reasons for not achieving SVR12 by ARV regimen

  Virologic Response              TDF+FTC+EFV (*n*=160)   TDF+FTC+RAL (*n*=146)   TDF+FTC+RPV (*n*=29)   Overall (*n*=335)
  ------------------------------- ----------------------- ----------------------- ---------------------- -------------------
  SVR12, *n* (%)                  151 (94)                141 (97)                28 (97)                320 (96)
  On-Treatment Failure, *n* (%)   1 (\<1)                 0                       1 (3)                  2 (\<1)
  Relapse, *n* (%)                8 (5)                   2 (1)                   0                      10 (3)
  Other, *n* (%)                  0                       1 (\<2)                 0                      2 (\<1)

###### 

TAF versus TDF single-tablet-regimen in HIV-1-infected women

                                                                      TAF (*n*=133)   TDF (*n*=127)   *p*-value
  ------------------------------------------------------------------- --------------- --------------- -----------
  Median baseline HIV viral load (log10 copies/mL)                    4.50            4.46            0.70
  Median baseline CD4 (/µL)                                           358             367             0.75
  Virologic success at W48, %                                         95%             87%             0.023
  Median change in CD4 (/µL) at W48                                   216             181             0.37
  Discontinuation due to treatment-emergent adverse events (AEs), %   0               1.6             0.24
  Treatment-emergent grade 3 or 4 AEs, %                              9               11.8            0.54
  PRT (proximal renal tubulopathy), *n*                               0               0               --
  Median changes in eGFR (mL/min), W48                                −5.4            −12.6           \<0.001
  Median % changes in UPCR (urine protein/creatinine mg/g), W48       −9.7            −1.2            0.31
  Median % changes in UACR (urine albumin/creatinine mg/g), W48       −4.1            +8.3            0.40
  Mean % changes in spine BMD, W48                                    −0.959          −2.912          \<0.001
  Mean % changes in hip BMD, W48                                      −1.255          −3.475          \<0.001

![Yearly HIV testing at Condesa Specialized Clinic.](JIAS-19-21047-g001){#F0003_21047}

###### 

Rates of HIV among MARPs diagnosed at Condesa Specialized Clinic

  ------------------------------------------------------------------------------------------------------------------------------------
  Population Group                                                                        HIV Prevalence (%)   Rate HIV+/\# of tests
  --------------------------------------------------------------------------------------- -------------------- -----------------------
  Transgender Women *n*=1.300                                                             41                   1 in 2.5

  Male Sex Workers *n*=627                                                                37                   1 in 2.5

  MSM *n*=15.547                                                                          19                   1 in 5

  Women partners of HIV positive men[\*](#TF0001_21047){ref-type="table-fn"} *n*= 7,110   3                    1 in 33

  Male Prison Inmates[\*](#TF0001_21047){ref-type="table-fn"} *n*=33.000                  1                    1 in 100

  Female Prison Inmates[\*](#TF0001_21047){ref-type="table-fn"} *n*=3,000                 1.10                 1 in 91

  Pregnant Women- D.F.\                                                                   0.22                 1 in 455
   Subway Clinics *n*=6,096\                                                                                   
   Public Health Clinics *n*=8,173\                                                                            
   HIV tests *n*=14.269                                                                                        

  Drug Users[\*\*\*](#TF0003_21047){ref-type="table-fn"} *n*=1.615                        1                    1 in 100

  Homeless Population[\*\*\*](#TF0003_21047){ref-type="table-fn"} *n*=155                 4.50                 1 in 22

  **Mexican Women** (ENSANUT 2012[\*\*](#TF0002_21047){ref-type="table-fn"})              **0.07**\            **1 in 1,428**\
                                                                                          **0.23**             **1 in 435**
  ------------------------------------------------------------------------------------------------------------------------------------

Prevalence of Project "Ponte a Prueba" 2010--2014.

Seroprevalence of general population in Mexico between 15 yand 49 yars: reasults from Ensanut 2012. Article published at Salud Pública de México/vol. 56, no. 4, julio-agosto de 2014.

Prevalences from Jefatura de Unidad Departamental de Programas Específicos

![Immune level at HIV diagnosis. 59.8% with CD4\>200](JIAS-19-21044-g001){#F0005_21044}

![The number and percentage of incarcerated people with HIV in different stages of care at the Santa Martha Acatitla Penitentiary in Mexico City during January -- October 2015 with 50.0% in virology control (VL\<40).](JIAS-19-21044-g002){#F0004_21044}

###### 

Unadjusted associations between selected time-varying factors and incident sexually transmitted infections

  Characteristics                                                                              Odds ratio      95% confidence limits
  -------------------------------------------------------------------------------------------- --------------- -----------------------
  Age greater than 24 years                                                                    0.76            0.30, 1.90
  Educational attainment                                                                                       
   Primary or secondary school                                                                 **Reference**   **Reference**
   High school                                                                                 0.28            0.09, 0.85
   College or post-graduate school                                                             0.13            0.03, 0.53
  Married                                                                                      1.34            0.18, 10.17
  Had stable romantic partner during last follow-up period                                     1.06            0.53, 2.13
  Had vaginal, anal or oral sex with five or more clients last week                            0.71            0.40, 1.27
  Used alcohol while having sex with any of three most recent clients                          0.81            0.33, 1.99
  Used a substance (drugs or alcohol) while having sex with any of three most recent clients   1.45            0.54, 3.88
  Perpetrated assault of any of three most recent clients                                      0.20            0.03, 1.36
  Frequently used condoms during sex in the past month                                         0.77            0.30, 1.94
  Had penetrative anal sex with any of 3 most recent clients                                   0.70            0.32, 1.55
  Had receptive anal sex with any of 3 most recent clients                                     1.04            0.47, 2.30

![Cascade of Care for MSM/TGW living with HIV in the Dominican Republic.](JIAS-19-21053-g001){#F0006_21053}

![Integrated Care Model to detect, evaluate, treat and retain new HIV patients in Mexico City.](JIAS-19-21057-g001){#F0007_21057}

![Healthcare flowchart of Mental Health Programme at Condesa Clinic.](JIAS-19-21058-g001){#F0008_21058}

![Bar chart of CD4 count completion and ART initiation rates by year.](JIAS-19-21059-g001){#F0009_21059}

![Median CD4 count at ART initiation.](JIAS-19-21060-g001){#F0010_21060}

![ART initiation of adult patients by trimester.](JIAS-19-21060-g002){#F0011_21060}

###### 

ART initiation of people living with HIV

  Year of ART initiation   2010   2011    2012     2013     2014     2015
  ------------------------ ------ ------- -------- -------- -------- --------
  *N*                      8645   9002    10,181   10,593   11,457   14,092
  Monthly average          720    750     848      883      955      1174
  Annual change            --     4.13%   13.10%   4.05%    8.16%    23.00%

###### 

Care model for HIV pregnant women

  Variable                                      Without prior HIV diagnosis (*N*=38)                                               With prior HIV diagnosis (*N*=17)                                                Vertical transmission of HIV (*N*=4)
  --------------------------------------------- ---------------------------------------------------------------------------------- -------------------------------------------------------------------------------- ----------------------------------------------------
  **Socio-demographic characteristics**                                                                                                                                                                             
  *Age* (average)                               24.1 years                                                                         25.4 years                                                                       19 years
  *Education*                                   *N*%                                                                               *N*%                                                                             *N*%
  Illiteracy                                    \(5\) 13.1                                                                         \(0\) 0                                                                          \(0\) 0
  Primary                                       \(12\) 31.5                                                                        \(3\) 17.6                                                                       \(0\) 0
  Secondary                                     \(14\) 38.8                                                                        \(7\) 41.1                                                                       \(2\) 50
  High school                                   \(4\) 10.5                                                                         \(5\) 29.4                                                                       \(2\) 50
  University                                    \(3\) 7.8                                                                          \(2\) 11.7                                                                       \(0\) 0
  *Occupation*                                  *N*%                                                                               *N*%                                                                             *N*%
  Housewife                                     \(26\) 68.4                                                                        \(11\) 64.7                                                                      \(3\) 75
  Employed                                      \(9\) 23.6                                                                         \(4\) 23.4                                                                       \(0\) 0
  Other                                         \(2\) 5.2                                                                          \(2\) 11.7                                                                       \(0\) 0
  Student                                       \(1\) 2.6                                                                          \(0\) 0                                                                          \(1\) 25
  *Marital status*                              *N*%                                                                               *N*%                                                                             *N*%
  Common marriage                               \(29\) 76.3                                                                        \(9\) 52.9                                                                       \(2\) 50
  Single                                        \(8\) 21                                                                           \(6\) 35.2                                                                       \(1\) 25
  Married                                       \(1\) 2.6                                                                          \(2\) 11.7                                                                       \(1\) 25
  *Partner*                                     *N*%                                                                               *N*%                                                                             *N*%
  Serodiscordant                                \(12\) 31.5                                                                        \(9\) 52.9                                                                       \(4\) 100
  Concordant                                    \(21\) 55.2                                                                        \(2\) 11.7                                                                       \(0\) 0
  Unknown                                       \(5\) 13.1                                                                         \(6\) 35.2                                                                       \(0\) 0
  *Drug use*                                    *N*%                                                                               *N*%                                                                             *N*%
  Yes, during pregnancy                         \(4\) 10.5                                                                         \(1\) 5.8                                                                        \(0\) 0
  **Characteristics of HIV infection**                                                                                                                                                                              
  Initial viral load (copies/mL)                Median 10,490 c/mL (SD 141,677)                                                    52.9% detectable Median 17,000 c/mL (SD 459,179) Only 47% undetectable (*n*=8)   100% detectable Median 11,749 c/mL (SD 13,276)
  Initial CD4 (c/µL)                            Median 336 c/µL (SD 189.5)                                                         Median 366 c/µL (SD 277.7)                                                       Median 316 c/µL (SD 99.9)
  *HAART*                                       *N*%                                                                               *N*%                                                                             *N*%
  RAL+TDF/FTC                                   \(16\) 42.1                                                                        \(3\) 17.6                                                                       \(0\) 0
  ATV/R+TDF/FTC                                 \(12\) 31.5                                                                        \(6\) 35.2                                                                       \(0\) 0
  LPV/R+3TC/AZT                                 \(8\) 21                                                                           \(2\) 11.7                                                                       \(2\) 50
  TDF/FTC/EFV                                   \(0\) 0                                                                            \(4\) 23.5                                                                       \(0\) 0
  LPV/R+ TDF/FTC                                \(2\) 5.2                                                                          \(2\) 11.7                                                                       \(2\) 50
  Weeks on HAART after HIV diagnosis (median)   Median 9 weeks (SD 8.1)                                                            Median 18 weeks (SD 9.7)                                                         Median 24 weeks (SD 6.7)
  Final VL c/mL                                 73.6% undetectable (*n*=28), 26.3% detectable (*n*=10), median 429 (D.E. 10,361)   64.7% undetectable (*n*=11), 35.2% detectable (*n*=6), median 124.5 (D.E.189)    75% (*n*=3) undetectable, 25% detectable (57 c/mL)
  Final CD4 c/uL                                Median 352 (SD 168)                                                                Median 418 (SD 207)                                                              Median 185 (SD 180)
  Quit treatment after giving birth             18.4% (*n*=7)                                                                      23.5% (*n*=4)                                                                    25% (*n*=1)
  **OB/GYN results**                                                                                                                                                                                                
  *Number of pregnancies*                       *N*%                                                                               *N*%                                                                             *N*%
  First time                                    \(13\) 34.2                                                                        \(10\) 58.8                                                                      \(4\) 100
  Second time                                   \(10\) 26.3                                                                        \(3\) 17.6                                                                       \(0\) 0
  Third or more                                 \(15\) 39.4                                                                        \(4\) 10.5                                                                       \(0\) 0
  *Pregnancy weeks at time of HIV diagnosis*    Median 25.7 weeks (S.D. 8.1)                                                       Median 20 weeks (S.D. 9.8)                                                       Median 14.3 weeks (S.D. 6.7)
  *Pregnancy resolution*                        *N*%                                                                               *N*%                                                                             *N*%
  Natural birth                                 \(1\) 2.6                                                                          \(3\) 17.6                                                                       \(1\) 25
  C-section                                     \(37\) 97.3                                                                        \(14\) 82.3                                                                      \(3\) 75
  *OB/GYN complications*                        \_                                                                                 Premature birth due to severe preeclampsia 5.8%                                  Premature birth due to HELLP syndrome 25%
  *Baby weight at birth* (median)               2,663 g (SD 449)                                                                   2,568 g (SD 424.9)                                                               2,436 g (SD 568)
  *Birth planning method*                       *N*%                                                                               *N*%                                                                             *N*%
  Definitive (bilateral tubal obstruction)      \(25\) 65.7                                                                        \(12\) 70.5                                                                      \(1\) 25
  Transdermal implants                          \(2\) 5.2                                                                          \(2\) 11.7                                                                       \(2\) 50
  IUD                                           \(6\) 15.7                                                                         \(0\) 0                                                                          \(1\) 25
  None                                          \(5\) 13.1                                                                         \(3\) 17.6                                                                       \(0\) 0
  HPV (cervical cytology)                       \(4\) 10.5                                                                         \(6\) 35.2                                                                       \(1\) 25

![Proportion of screening tests among HIV positive adults.](JIAS-19-21063-g001){#F0012_21063}

![Percentage increase/decrease in AIDS mortality by state from 2003 to 2013.](JIAS-19-21065-g001){#F0013_21065}

![25 municipalities with the highest AIDS mortality rates from 2009 to 2013.](JIAS-19-21065-g002){#F0014_21065}

  SVR at W96   SINGLE DTG--EFV   SPRING---2 DTG--RAL   FLAMINGO DTG--DRV/r
  ------------ ----------------- --------------------- ---------------------
  PPV (%)      87---73           84---85               82---70
  NPV (%)      32---28           28---39               26---32

![Treatment GAP of Brazilian states (aged 18 and over), 2015.](JIAS-19-21069-g001){#F0015_21069}

![Proportion of PLWHA eligible for HAART who did not start treatment (GAP) by age group. Brazil, 2009--2015.](JIAS-19-21069-g002){#F0016_21069}

![Low-level viraemia prevalence after 24 weeks on ART at Mexico MoH, 2015.](JIAS-19-21070-g001){#F0017_21070}

![VL after 24 weeks on ART at Mexico MoH by sex and regimen, 2015.](JIAS-19-21070-g002){#F0018_21070}

###### 

Demographic data and results from clinical trials and RWE studies using LDC/SOF for 8 weeks

  Study            ION-3        TARGET                                               TRIO         Buggisch                                             GECCO                                                VA -- Marshall   Ruane        Total (non ION3)
  ---------------- ------------ ---------------------------------------------------- ------------ ---------------------------------------------------- ---------------------------------------------------- ---------------- ------------ ------------------
  N/N (GT 1)       119/123      150/154                                              251/263      103/103                                              69/70                                                47/48            18/20        638/658
  Age (mean)       52 (22-73)   58[\*](#TF0001_21074){ref-type="table-fn"} (19-84)   57 (18-84)   50[\*](#TF0001_21074){ref-type="table-fn"} (22-77)   52[\*](#TF0001_21074){ref-type="table-fn"} (44-58)   61 (32-75)       52 (35-66)   n/a
  HIV/HCV          0            1/1                                                  3/3          3/3                                                  7/7                                                  0                18/20        32/34
  VL \>6 million   0            0                                                    8/8          0                                                    9/9                                                  0                0            17/17
  Cirrhotics       0            6/6                                                  0            0                                                    3/3                                                  0                0            9/9
  GT 4             0            0                                                    0            2/2                                                  0                                                    0                0            2/2
  Tx Exp           0            8/8                                                  0            1/1                                                  12/12                                                5/5              0            26/26
  SVR12 (%)        97%          97%                                                  95%          100%                                                 99%                                                  98%              90%          97%

Median age used

###### 

Summary of pVL at PDVF and by reportable results according to class.

                                     PDVF   Reportable Results[†](#TF0001_21079){ref-type="table-fn"}   Resistance Detected[\#](#TF0002_21079){ref-type="table-fn"}                                                             
  -------------------- ----- ------- ------ ----------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------- ------- ------------------------
  **SINGLE Wk 144**    414   DTG     39     2.14 (1.72--5.61)                                           19:26                                                         IN: 3.13 (1.72--5.61)/ PR/RT: 2.59 (1.82--5.61)   0 : 0   na
                       419   ATR     33     2.07 (1.70--4.91)                                           11:16                                                         IN:3.82 (1.75--4.91)/ PR/RT: 3.12 (1.70--4.91)    0 : 7   3.84 (2.12--4.61)
  **SPRING-2 Wk 96**   411   DTG     22     1.94 (1.71--4.09)                                           10:14                                                         IN: 2.20 (1.76--4.09)/ PR/RT: 2.36 (1.73--4.09)   0 : 0   na
                       411   RAL     29     1.93 (1.70--4.95)                                           20:20                                                         IN: 1.93 (1.70--4.95)/ PR/RT: 2.10 (1.72--4.95)   1 : 4   4.95 1.96 (1.72--4.95)
  **FLAMINGO Wk 96**   242   DTG     2      3.17 (2.82, 3.36)                                           2:2                                                           IN: 3.17 (2.82--3.36)/ PR/RT: 3.17 (2.82--3.36)   0 : 0   na
                       242   DRV/r   4      3.62 (2.34--4.79)                                           4:4                                                           IN: 3.62 (2.34--4.79)/ PR/RT: 3.62 (2.34--4.79)   0 : 0   na

IN: Integrase, PR/RT: protease/reverse transcriptase;

na=not applicable.
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